NCT03223220Not yet recruitingPhase 2/3
Quelling of Excitotoxicity in Acute Stroke With Ketamine
Source: ClinicalTrials.gov · Last updated 18 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 14 Jul 2017
- Start date
- 1 Jul 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Lower Merion Neurology Research Foundation
- Diseases
- Stroke
- NCT number
- NCT03223220
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 120
- From 1 Jul 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known hypersensitivity or adverse reaction to prior administration of Ketamine
Other illness
- Pre-stroke modified Rankin scale of 3 or above.
- Pre-existing psychiatric illness
- Intracranial hemorrhage of any type at presentation
- Seizure at onset of symptoms
- Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications
Other
- Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy
- Longer than 24 hours since last known well time
- Pregnant or lactating females
- Inability/refusal to provide consent by the patient or through a proxy
Who the study is looking for
- All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time
- An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate
- Pre-stroke modified Rankin scale of 0-2
- Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lankenau Medical Center Coordinator of this site? Confirm its status | Wynnewood | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.